Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
August 12, 2022 at 02:44 pm EDT
Share
Regenicin, Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported net loss was USD 0.163093 million compared to USD 0.165345 million a year ago.
For the nine months, net loss was USD 0.483867 million compared to USD 0.558527 million a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
REGENICIN, INC. 
